Exact Mass: 320.1637

Exact Mass Matches: 320.1637

Found 15 metabolites which its exact mass value is equals to given mass value 320.1637, within given mass tolerance error 0.0002 dalton. Try search metabolite list with more accurate mass tolerance error 4.0E-5 dalton.

2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide

C19H20N4O (320.1637)


D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors

   

MMV687706

MMV687706

C19H20N4O (320.1637)


   

2-(4-benzylpiperazin-1-yl)-1H-quinazolin-4-one

2-(4-benzylpiperazin-1-yl)-1H-quinazolin-4-one

C19H20N4O (320.1637)


   

6-(7-methyl-4-piperazin-1-yl-1H-quinazolin-2-ylidene)cyclohexa-2,4-dien-1-one

6-(7-methyl-4-piperazin-1-yl-1H-quinazolin-2-ylidene)cyclohexa-2,4-dien-1-one

C19H20N4O (320.1637)


   

(E)-3-[2-(Pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine

(E)-3-[2-(Pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine

C19H20N4O (320.1637)


   

Niraparib

MK-4827(Niraparib)

C19H20N4O (320.1637)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XK - Poly (adp-ribose) polymerase (parp) inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor

   

Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-

Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-

C19H20N4O (320.1637)


   

(R)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

(R)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

C19H20N4O (320.1637)


   

(Z)-2-cyano-3-(7-methyl-2-piperidin-1-ylquinolin-3-yl)prop-2-enamide

(Z)-2-cyano-3-(7-methyl-2-piperidin-1-ylquinolin-3-yl)prop-2-enamide

C19H20N4O (320.1637)


   

3-(6-Aminopyridin-3-YL)-N-methyl-N-[(1-methyl-1H-indol-2-YL)methyl]acrylamide

3-(6-Aminopyridin-3-YL)-N-methyl-N-[(1-methyl-1H-indol-2-YL)methyl]acrylamide

C19H20N4O (320.1637)


   

1-[5-(4-phenoxyphenyl)-1H-pyrazol-3-yl]piperazine

1-[5-(4-phenoxyphenyl)-1H-pyrazol-3-yl]piperazine

C19H20N4O (320.1637)


   

N-[2-(2-pyridinyl)-3H-benzimidazol-5-yl]cyclohexanecarboxamide

N-[2-(2-pyridinyl)-3H-benzimidazol-5-yl]cyclohexanecarboxamide

C19H20N4O (320.1637)


   

cyclopropyl-[(1S,5R)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone

cyclopropyl-[(1S,5R)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methanone

C19H20N4O (320.1637)


   

2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

C19H20N4O (320.1637)


D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors

   

ABT-107

ABT-107

C19H20N4O (320.1637)


ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions[1][2].